The results obtained from the Western blot analysis proved its selectivity toward glioblastoma cell line DBTRG.05-MG harboring EGFR, which showed that compound 143 has the capability of inhibiting the EGFR downstream signaling (Pédeboscq et al., 2010). The gene discussed is EGFR; the disease is glioblastoma.